for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ADMA Biologics Inc

ADMA.OQ

Latest Trade

2.86USD

Change

0.00(-0.00%)

Volume

571,533

Today's Range

2.84

 - 

2.99

52 Week Range

1.46

 - 

5.48

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.86
Open
2.94
Volume
571,533
3M AVG Volume
67.04
Today's High
2.99
Today's Low
2.84
52 Week High
5.48
52 Week Low
1.46
Shares Out (MIL)
86.35
Market Cap (MIL)
250.40
Forward P/E
-4.42
Dividend (Yield %)
--

Next Event

ADMA Biologics Inc Annual Shareholders Meeting

Latest Developments

More

ADMA Biologics Reports Q4 Loss Per Share Of $0.18

ADMA Biologics Announces Proposed $75 Million Public Offering Of Common Stock

ADMA Biologics Says Q4 Revenue Rose 193% To $11.9 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ADMA Biologics Inc

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

Industry

Biotechnology & Drugs

Contact Info

C/O Adma Biologics

Inc., 465 State Route 17

RAMSEY, NJ

07446

United States

+1.201.4785552

https://www.admabiologics.com/

Executive Leadership

Steven A. Elms

Chairman of the Board

Adam S. Grossman

President, Chief Executive Officer, Co-Founder, Director

Jerrold B. Grossman

Vice Chairman of the Board, Co-Founder

Brian Lenz

Chief Financial Officer, Executive Vice President

James Mond

Chief Scientific and Medical Officer

Key Stats

1.71 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.1K
EPS (USD)

2017

-1.650

2018

-1.450

2019

-0.890

2020(E)

-0.692
Price To Earnings (TTM)
--
Price To Sales (TTM)
6.95
Price To Book (MRQ)
2.60
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
99.79
LT Debt To Equity (MRQ)
99.79
Return on Investment (TTM)
-40.88
Return on Equity (TTM)
-37.73

Latest News

Latest News

BRIEF-Adma Biologics Commences Collection Of Covid-19 Plasma From Recovered Patients

* ADMA BIOLOGICS COMMENCES COLLECTION OF COVID-19 PLASMA FROM RECOVERED PATIENTS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Adma Biologics Conformance Batch Production For Bivigam Is At Double Plasma Volume Of Current FDA Approved Process

* ADMA BIOLOGICS INC - CONFORMANCE BATCH PRODUCTION FOR BIVIGAM IS AT DOUBLE PLASMA VOLUME OF CURRENT FDA APPROVED PROCESS

BRIEF-Adma Biologics Unit Received Funding Pursuant To Promissory Note

* ADMA BIOLOGICS INC - UNIT RECEIVED FUNDING PURSUANT TO PROMISSORY NOTE EVIDENCING UNSECURED LOAN OF ABOUT $5.4 MILLION UNDER PAYCHECK PROTECTION PROGRAM Source text: (http://www.sec.gov/archives/edgar/data/1368514/000119380520000502/0001193805-20-000502-index.htm) Further...

BRIEF-4Sc: FDA Accepts IND Application For MERKLIN 2 Study

* INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR DOMATINOSTAT IN COMBINATION WITH AVELUMAB (BAVENCIO(R)) HAS BEEN ACCEPTED BY U.S. FOOD AND DRUG ADMINISTRATION (FDA) Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-ADMA Biologics Reports Q4 Loss Per Share Of $0.18

* ADMA BIOLOGICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS

BRIEF-ADMA Biologics Highlights Expanded Intellectual Property Portfolio For Specialty Plasma Derived Immune Globulins Targeted Against Respiratory Infections

* ADMA BIOLOGICS HIGHLIGHTS EXPANDED INTELLECTUAL PROPERTY PORTFOLIO FOR SPECIALTY PLASMA DERIVED IMMUNE GLOBULINS TARGETED AGAINST RESPIRATORY INFECTIONS Source text for Eikon: Further company coverage:

UPDATE 1-FDA declines to approve re-launch of ADMA Biologics' Bivigam

The U.S. Food and Drug Administration (FDA)on Wednesday declined to approve ADMA Biologics Inc's application to re-launch its immune deficiency treatment Bivigam, the company said.

FDA declines to approve re-launch of ADMA Biologics' Bivigam

The U.S. Food and Drug Administration on Wednesday declined to approve ADMA Biologics Inc's application to re-launch its immune deficiency treatment Bivigam, the company said.

BRIEF-ADMA Biologics Files For Mixed Shelf Offering Of Up To $100 Mln

* ADMA BIOLOGICS FILES FOR MIXED SHELF OFFERING OF UP TO $100 MILLION - SEC FILING Source http://bit.ly/2IrSugh Further company coverage:

BRIEF-Adma Biologics Granted U.S. Patent For Treating Respiratory Infections

* ADMA BIOLOGICS GRANTED U.S. PATENT FOR TREATING RESPIRATORY INFECTIONS

BRIEF-ADMA Biologics Q1 Loss Per Share $0.39

* ADMA BIOLOGICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-ADMA Biologics Retires About 8.6 Million Shares Previously Issued to Biotest

* ADMA BIOLOGICS INC - RETIRES APPROXIMATELY 8.6 MILLION SHARES PREVIOUSLY ISSUED TO BIOTEST PHARMACEUTICALS CORPORATION AND ITS FORMER PARENT, BIOTEST AG

BRIEF-ADMA Biologics Releases Its First Commercial Batch Of Nabi-HB Manufactured Under Its Ownership

* ADMA BIOLOGICS ANNOUNCES THE RELEASE OF ITS FIRST COMMERCIAL BATCH OF NABI-HB MANUFACTURED UNDER ITS OWNERSHIP

BRIEF-ADMA Files Biologics License Application For Its Third Plasma Collection Center

* ADMA FILES BIOLOGICS LICENSE APPLICATION FOR ITS THIRD PLASMA COLLECTION CENTER

BRIEF-Adma Biologics prices follow-on offering of 17.0 mln shares

* Adma Biologics Inc - pricing of offering of approximately 17.0 million shares of its common stock at price of $2.15 per share Source text for Eikon: Further company coverage:

BRIEF-ADMA Biologics now sees offering of 13.6 mln shares of common stock - SEC filing

* Now sees offering of 13.6 million shares of its common stock, up from previous filing of 10.2 million shares - SEC filing Source text: (http://bit.ly/2zmNV1L) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-ADMA Biologics Q3 loss per share $0.59

* ADMA Biologics provides corporate update and reports third quarter 2017 financial results

BRIEF-ADMA Biologics says ‍loss per share was $0.59 for fiscal quarter ended Sept 30​

* ADMA Biologics Inc says for fiscal quarter ended September 30, loss per share was $0.59 - SEC filing

BRIEF-Adma Biologics Inc files for offering of up to $28.75 million of common stock

* Adma Biologics Inc files for offering of up to $28.75 million of common stock Source text: (http://bit.ly/2gvC2f8) Further company coverage:

BRIEF-ADMA Biologics ‍enters into credit agreement for up to $40 mln with affiliated entities of Marathon Asset Management​

* ADMA Biologics Inc - entered into a credit agreement for up to $40 million with affiliated entities of marathon asset management

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up